Navigation Links
Protalix BioTherapeutics to Dual List on Tel Aviv Stock Exchange
Date:8/30/2010

rl=http://content.prnewswire.com/designimages&skill=voice' id="voiceimage" border="0" style="display:none;" > --> Biotechnology, Health Care & Hospitals, Medical Pharmaceuticals Click to view news release full screen  

Protalix BioTherapeutics to Dual List on Tel Aviv Stock Exchange

   

- Common Stock to List on both Tel Aviv Stock Exchange and the NYSE Amex Beginning Monday, September 6, 2010 under the Ticker Symbol PLX -- Company Anticipates Joining TASE's TA-75, TA-100, Tel-Tech, Tel-Tech 15 and Biomed indexes beginning October 10, 2010

CARMIEL, Israel, Aug. 30 /PRNewswire-FirstCall/ -- Protalix BioTherapeutics, Inc., (NYSE Amex: PLX), a biopharmaceutical company focused on the development and commercialization of recombinant therapeutic proteins expressed through its proprietary plant cell based expression system, today announced that the Company's common stock has been approved for listing on the Tel Aviv Stock Exchange in addition to its current listing on the NYSE Amex. Trading of the Company's common stock on the Tel Aviv Stock Exchange will commence on September 6, 2010. The Company also announced today that, based upon the Company's current market capitalization, it expects its common stock to be included in the TA-75, TA-100, Tel-Tech, Tel-Tech 15 and Biomed indexes beginning October
'/>"/>

SOURCE Protalix BioTherapeutics, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8

Related biology technology :

1. Protalix Announces Successful GMP Manufacturing Audit by Israels Ministry of Health
2. Integrated BioTherapeutics Awarded NIAID Contract For Up to $65 Million for Development of a Vaccine against Ebola and Marburg Viruses
3. Northwest Biotherapeutics Settles Class Action Complaint, and SEC Investigation Closed Without Action
4. Northwest Biotherapeutics Secures $700,000 Equity Financing
5. Oxygen Biotherapeutics, Inc. Expands Board of Directors
6. Oxygen Biotherapeutics, Inc. Adds Oxycyte TBI Clinical Trial Sites in Israel
7. Webcast Alert: Oxygen Biotherapeutics, Inc. Investor Meeting in Zurich, Switzerland
8. Oxygen Biotherapeutics, Inc. CEO Posts New Blog Entry
9. Oxygen Biotherapeutics, Inc. Signs Supply Agreement for Clinical-Grade Oxycyte for Clinical Trials and Future Needs
10. CSL Limited and Talecris Biotherapeutics Agree to Terminate Merger Agreement
11. Oxygen Biotherapeutics, Inc. Announces Closing of Private Placement Financing Agreement
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/26/2015)... 26, 2015 Global Stem Cells ... plans for the company’s first cellular and regenerative medicine ... a full day, hands-on stem cell training class Oct. ... Garcia Gimenez, M.D., President of Therapeutic Confrontations (CONFTERA) in ... increasing interest in regenerative medicine and recent advances in ...
(Date:5/26/2015)... Texas , May 26, 2015  A simple ... Health Science Center to detect early Alzheimer,s disease is ... adults. Detailed standardized guidelines that are needed ... have been published in Alzheimer,s & Dementia . ... of an international working group that includes UNT Health ...
(Date:5/26/2015)... mája 2015 Kevin Xu , ... prezidentom Barackovi Obamovi a Billovi Clintonovi za ich ... Dr. Rongxiang Xu , otca Kevina. ... Dr. Xu bol pionier, inovátor, humanitárny pracovník ... v oblasti vedy a príkladné vedenie svojej komunity ...
(Date:5/26/2015)... 26, 2015 Oramed Pharmaceuticals Inc. ... pharmaceutical company focused on the development of oral drug ... study protocol for the company,s Phase IIb trial of ... and Drug Administration (FDA). The submission was made under ... The Phase IIb study of ORMD-0801 for type ...
Breaking Biology Technology:Stem Cell Training, Inc. Announces First European Symposium on Cellular and Regenerative Medicine 2Stem Cell Training, Inc. Announces First European Symposium on Cellular and Regenerative Medicine 3Guidelines bring UNT Health Science Center's blood test for Alzheimer's one step closer 2Dr. Rongxiang Xu, O legende 2Oramed Submits Protocol to U.S. FDA for Its Phase IIb Oral Insulin Study 2Oramed Submits Protocol to U.S. FDA for Its Phase IIb Oral Insulin Study 3
... Therapeutics,(Nasdaq: NKTR ) today announced that ... pulmonary delivery assets, technology, and intellectual,property to Novartis ... completed,on December 31, 2008. , ... certain dry powder and,liquid pulmonary formulation and manufacturing ...
... to announce the 3rd Global Jatropha Hi-Tech Agricultural Training Programme ... privilege to provide most authoritative Knowledge platform known as Global ... Jatropha Oil Crop Projects, Programmes and Priorities to Feed Biodiesel ... ...
... Merial, a world leading animal health,company, and the ... Merial to obtain exclusive rights to Imugene vector,technology. ... the product development process to global sales. Additional ... and, if successful, will,also progress into the product ...
Cached Biology Technology:Nektar Announces Closing of Sale of Specific Pulmonary Delivery Assets to Novartis for $115 Million 2CJP Declares the Dates of 3rd Global Jatropha Hi-Tech Agricultural Training Programme 2CJP Declares the Dates of 3rd Global Jatropha Hi-Tech Agricultural Training Programme 3CJP Declares the Dates of 3rd Global Jatropha Hi-Tech Agricultural Training Programme 4Imugene and Merial Establish Strategic Alliance 2
(Date:5/11/2015)... May 11, 2015  Synaptics Incorporated (NASDAQ: ... solutions, today announced the appointment of Wajid ... Financial Officer, reporting to Rick Bergman , ... Chief Financial Officer, Kathleen Bayless , who ... Mr. Ali brings extensive financial management expertise ...
(Date:5/10/2015)... , May 11, 2015 Fingerprint Cards ... FPC1025 and FPC1155 from the distributor World Peace Industrial Group ... distributors in Asia . Deliveries are planned ... be used by smartphone manufacturers in China ... the communicated revenue guidance of + 1 000 MSEK for 2015. ...
(Date:5/6/2015)... , May 6, 2015 LifeBEAM, a ... established helmet producer, announced today that they will expand ... the world,s first bio-sensing cycling helmet and the first ... in two new colors in order to give cyclists ... product. In addition, LifeBEAM and Lazer announced their plan ...
Breaking Biology News(10 mins):Synaptics Appoints Wajid Ali as Senior Vice President and Chief Financial Officer 2Fingerprint Cards Receives Touch Fingerprint Sensor Order of SEK 235 Million 2LifeBEAM and Lazer Announce Expanded Partnership in Bio-Sensing Sports Gear 2LifeBEAM and Lazer Announce Expanded Partnership in Bio-Sensing Sports Gear 3
... University School of Medicine has helped confirm the reliability ... ushering in the long-promised era of personalized medicine based ... one of the five sites that helped determine that ... risk of developing cirrhosis from chronic hepatitis C infection. ...
... hospitals in Peru has shown that opening windows and ... ventilated negative-pressure rooms and 18 times that of rooms ... led by Rod Escombe from Imperial College London, compared ... as respiratory isolation rooms, TB wards, respiratory wards, general ...
... called lupus, is a complex autoimmune disease marked ... depression, among other symptoms. Some studies have described ... manifestation, psychosis, and a protein autoantibody associated with ... , To investigate how an autoantibody could stimulate ...
Cached Biology News:New test helps identify hepatitis C patients at high risk of developing cirrhosis 2New test helps identify hepatitis C patients at high risk of developing cirrhosis 3New insights into autoimmunity and depression 2
Barcoded Slides, 5 Packs of 5 Slides (25/Case)...
Adult Bovine Serum US Origin...
Anti-Mouse Qa.m8, Ascites (Clone 5035-24.1) (mouse IgG3)...
... 13(S)-HODE-d4 contains 4 deuterium atoms at the 9, ... for use as an internal standard for the ... 13(S)-HODE is produced by incubation of linoleic acid ... shown to inhibit the adhesion of tumor cells ...
Biology Products: